Table 4 |
|||
|
Serious adverse events occurring in patients switching between TNF antagonists |
|||
|
1st TNF antagonist (n = 417) |
2nd TNF antagonist (n = 83) |
3rd TNF antagonist (n = 18) |
|
|
|
|||
|
Upper respiratory infections |
8 |
1 |
|
|
Urticaria |
3 |
||
|
Systemic lupus erythematosus |
2 |
||
|
Herpes zoster |
2 |
||
|
Rash |
3 |
1 |
1 |
|
Tuberculosis |
2 |
1 |
|
|
Infusion reactions |
16 |
1 |
|
|
Cardiac insufficiency |
3 |
||
|
Acute pancreatitis |
2 |
||
|
Cutaneous vasculitis |
2 |
||
|
Erythema |
3 |
||
|
Infectious arthritis |
2 |
||
|
Leukopenia |
1 |
||
|
|
|||
|
Navarro-Sarabia et al. BMC Musculoskeletal Disorders 2009 10:91 doi:10.1186/1471-2474-10-91 |
|||
